Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153396 | 1.00 | GRM5 (0.59) | GRM5CYP2D6CYP1A2CYP2A6KCNH2 | |
| SCHEMBL3796332 | 0.75 | CYP2A6 (0.67) | GRM5CYP2D6CYP1A2CYP2A6CHRNB2 | |
| SCHEMBL4712602 | 0.74 | GRM5 (1.00) | GRM5CYP2D6CYP1A2KCNH2CYP2C9 | |
| SCHEMBL31673255 | 0.74 | GRM5 (1.00) | GRM5CYP2D6CYP1A2KCNH2CYP2C9 | |
| SCHEMBL4158243 | 0.74 | GRM5 (0.57) | GRM5 | |
| SCHEMBL30273059 | 0.73 | GRM5 (1.00) | GRM5CYP2D6CYP1A2 | |
| SCHEMBL187254 | 0.73 | GRM5 (1.00) | GRM5CYP2D6CYP1A2 | |
| SCHEMBL31673197 | 0.72 | GRM5 (0.57) | GRM5CYP1A2KCNH2 | |
| Hydrochloric Acid SCHEMBL1803964 | 0.72 | GRM5 (0.97) | GRM5CYP2D6CYP1A2 | |
| SCHEMBL13907278 | 0.71 | CYP2A6 (0.62) | GRM5CYP2D6CYP1A2CYP2A6CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257076-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS | CGAS, SSB, FPGS | GRM5 2394/4885CYP2D6 3422/4885CYP1A2 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.